Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference
MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City. The presentation is available only to attendees of the conference: https://www.cantor.com/cantor-oncology-hemonc-conference/
Related news for (THTX)
- MoBot alert highlights: NASDAQ: CMND, NASDAQ: LRHC, NASDAQ: THTX, NASDAQ: WINT, NASDAQ: EMPG (07/03/25 08:00 AM)
- Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
- 24/7 Market News Snapshot 03 July, 2025 – Theratechnologies Inc. Common (NASDAQ:THTX)
- Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
- Theratechnologies Provides Update on Sale Process